DK3538542T3 - Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin - Google Patents

Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin Download PDF

Info

Publication number
DK3538542T3
DK3538542T3 DK17870529.9T DK17870529T DK3538542T3 DK 3538542 T3 DK3538542 T3 DK 3538542T3 DK 17870529 T DK17870529 T DK 17870529T DK 3538542 T3 DK3538542 T3 DK 3538542T3
Authority
DK
Denmark
Prior art keywords
peptime
multimizes
4beta
alfa
integrin
Prior art date
Application number
DK17870529.9T
Other languages
English (en)
Inventor
Monzur M Morshed
Sai Kumar Chakka
Jennifer L Hickey
Manuel Perez Vazquez
Andrew Roughton
Adam Paul Kafal
Narendrakumar B Patel
Original Assignee
Zealand Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma As filed Critical Zealand Pharma As
Application granted granted Critical
Publication of DK3538542T3 publication Critical patent/DK3538542T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/52—Cyclic peptides containing at least one abnormal peptide link with only normal peptide links in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/12—Cyclic peptides with only normal peptide bonds in the ring
    • C07K5/126—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK17870529.9T 2016-11-11 2017-11-10 Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin DK3538542T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662421117P 2016-11-11 2016-11-11
PCT/CA2017/000244 WO2018085921A1 (en) 2016-11-11 2017-11-10 CYCLIC PEPTIDES MULTIMERS TARGETING α4β7 INTEGRIN

Publications (1)

Publication Number Publication Date
DK3538542T3 true DK3538542T3 (da) 2021-10-11

Family

ID=62110102

Family Applications (1)

Application Number Title Priority Date Filing Date
DK17870529.9T DK3538542T3 (da) 2016-11-11 2017-11-10 Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin

Country Status (8)

Country Link
US (3) US11111273B2 (da)
EP (2) EP3538542B1 (da)
JP (2) JP7035044B2 (da)
CN (1) CN110088121A (da)
CA (1) CA3042576A1 (da)
DK (1) DK3538542T3 (da)
ES (1) ES2884107T3 (da)
WO (1) WO2018085921A1 (da)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2884107T3 (es) * 2016-11-11 2021-12-10 Zealand Pharma As Multímeros de péptidos cíclicos con diana en la integrina alfa-4 beta-7
US11286281B2 (en) 2017-05-10 2022-03-29 Zealand Pharma A/S Homodetic cyclic peptides targeting alpha-4-beta-7 integrin
US20230033021A1 (en) 2018-06-20 2023-02-02 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
EP4101929A4 (en) * 2019-12-27 2024-05-22 The University of Tokyo BANK CONSTRUCTION METHOD, CYCLIC PEPTIDE, FXIIA BINDER AND IFNGR1 BINDER
JP2021106565A (ja) * 2019-12-27 2021-07-29 国立大学法人 東京大学 ライブラリーの製造方法、環状ペプチド、ＦＸＩＩａ結合剤、及びＩＦＮＧＲ１結合剤
US20230295235A1 (en) * 2020-06-29 2023-09-21 Zealand Pharma A/S Compounds targeting alpha4-beta7 integrin
US20250057912A1 (en) 2021-12-20 2025-02-20 Zealand Pharma A/S Compounds

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3219113A1 (de) 1982-05-21 1983-11-24 Bayer Ag, 5090 Leverkusen Verwendung von n-substituierten 2,3-diaminocarbonsaeuren in arzneimitteln und ihre herstellung
ZA906188B (en) 1989-08-10 1991-06-26 Merrell Dow Pharma Cyclic neurokinin a antagonists
US5296604A (en) 1992-05-15 1994-03-22 Miles Inc. Proline derivatives and compositions for their use as inhibitors of HIV protease
US5705481A (en) 1992-11-06 1998-01-06 Merck Patent Gesellschaft Mit Beschrankter Haftung Cyclopeptides
AU681119B2 (en) 1993-05-17 1997-08-21 Fujisawa Pharmaceutical Co., Ltd. New polypeptide compound and a process for preparation thereof
US5693325A (en) 1994-03-15 1997-12-02 Molecumetics, Ltd. Peptide vaccines and methods relating thereto
DE4415310A1 (de) 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptide
AU2958195A (en) 1994-06-29 1996-01-25 Texas Biotechnology Corporation Process to inhibit binding of the integrin alpha 4 beta 1 to vcam-1 or fibronectin
GB9524630D0 (en) 1994-12-24 1996-01-31 Zeneca Ltd Chemical compounds
US6034057A (en) 1995-07-06 2000-03-07 Zeneca Limited Peptide inhibitors of fibronectine
US6248713B1 (en) 1995-07-11 2001-06-19 Biogen, Inc. Cell adhesion inhibitors
US5696084A (en) 1996-08-16 1997-12-09 Abbott Laboratories Amino-lipopetide antifungal agents
US6492553B1 (en) 1998-01-29 2002-12-10 Aventis Pharamaceuticals Inc. Methods for preparing N-[(aliphatic or aromatic)carbonyl)]-2-aminoaetamide compounds and for cyclizing such compounds
US6960597B2 (en) * 2000-06-30 2005-11-01 Orth-Mcneil Pharmaceutical, Inc. Aza-bridged-bicyclic amino acid derivatives as α4 integrin antagonists
DE10107707A1 (de) 2001-02-19 2002-08-29 Wilex Biotechnology Gmbh Antagonisten für alpha¶4¶beta¶7¶-Integrin
US6667407B2 (en) 2002-05-03 2003-12-23 Bayer Polymers Llc Process of making polyaziridines
US8129346B2 (en) 2004-04-15 2012-03-06 Onyx Therapeutics, Inc. Compounds for enzyme inhibition
CA2702605C (en) 2006-10-20 2015-03-24 Ryan Hili Unprotected amino aldehydes and applications for same
EP1961759A1 (en) 2007-02-21 2008-08-27 Universita'degli Studi Di Milano Integrin targeted cyclopeptide ligands, their preparation and use
EP2291390B1 (en) 2008-05-22 2014-11-05 Centre National de la Recherche Scientifique (CNRS) New optically pure compounds for improved therapeutic efficiency
PT2408802T (pt) 2009-03-16 2017-08-03 Governing Council Univ Toronto Moléculas de aminoácido ciclicas e métodos para as preparar
US20120045393A1 (en) 2009-03-17 2012-02-23 Linder Karen E Lhrh-ii peptide analogs
MX2012011549A (es) 2010-04-08 2013-01-29 Ah Usa 42 Llc Derivados de 3,5-difenil-isoxazolina sustituida como insecticidas y acaricidas.
EP2678350A1 (en) 2011-02-22 2014-01-01 Leo Pharma A/S A cyclic peptide and conjugate thereof for binding to keratinocytes
WO2013110578A1 (en) 2012-01-27 2013-08-01 F. Hoffmann-La Roche Ag Integrin antagonist conjugates for targeted delivery to cells expressing alpha-v-beta-3
WO2013161904A1 (ja) * 2012-04-24 2013-10-31 味の素株式会社 スルホンアミド誘導体及びその医薬用途
US9273093B2 (en) * 2012-10-11 2016-03-01 Protagonist Therapeutics, Inc. α4β7 peptide dimer antagonists
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
US10301371B2 (en) * 2014-10-01 2019-05-28 Protagonist Therapeutics, Inc. Cyclic monomer and dimer peptides having integrin antagonist activity
WO2016054411A1 (en) * 2014-10-01 2016-04-07 Protagonist Therapeutics, Inc. NOVEL α4β7 PEPTIDE MONOMER AND DIMER ANTAGONISTS
US11072616B2 (en) 2015-11-11 2021-07-27 Universite De Montreal Cyclic peptides targeting alpha-4-beta-7 integrin
ES2884107T3 (es) 2016-11-11 2021-12-10 Zealand Pharma As Multímeros de péptidos cíclicos con diana en la integrina alfa-4 beta-7

Also Published As

Publication number Publication date
EP3538542A1 (en) 2019-09-18
WO2018085921A1 (en) 2018-05-17
JP7035044B2 (ja) 2022-03-14
US20200216501A1 (en) 2020-07-09
US20230406884A1 (en) 2023-12-21
US11111273B2 (en) 2021-09-07
US20210324007A1 (en) 2021-10-21
US11713338B2 (en) 2023-08-01
EP3538542B1 (en) 2021-08-04
ES2884107T3 (es) 2021-12-10
CA3042576A1 (en) 2018-05-17
CN110088121A (zh) 2019-08-02
US12077611B2 (en) 2024-09-03
JP2020504080A (ja) 2020-02-06
JP7429726B2 (ja) 2024-02-08
EP3939989A1 (en) 2022-01-19
JP2022078188A (ja) 2022-05-24
EP3538542A4 (en) 2020-08-26

Similar Documents

Publication Publication Date Title
DK3519420T3 (da) Cykliske dinukleotidforbindelser
DK3405050T3 (da) Børnesikret snusbeholder
EP3440949A4 (en) FLAVOR INHALER
EP3596108A4 (en) TARGETED IMMUNOTOLERANCE
EP3446605A4 (en) HAND VACUUM
EP3720871A4 (en) TARGETED IMMUNOTOLERANCE
DK3436823T3 (da) Antigen-array
EP3515419A4 (en) High mobility group box i mutant
EP3455498A4 (en) Fuel delivery injector
EP3445380C0 (en) BACTERIOTHERAPY
DK3335532T3 (da) Tandharve
DK3402792T3 (da) Quinolin-2-on-derivater
EP3402022A4 (en) GRAB WIRE
EP3465295A4 (en) STACK OF POLARIZERS
DK3445708T3 (da) Stigbøjle
DK3538542T3 (da) Cykliske peptidmultimerer målrettet alfa-4beta-7-integrin
EP3402021A4 (en) GRAB WIRE
DK3509963T3 (da) Pallecontainer
EP3527618C0 (en) POLYOLEFIN STRUCTURE
EP3478921A4 (en) PULL CORD ARRANGEMENT
DK3528829T3 (da) Bacitracin-alginat-oligomer-konjugater
DK3575238T3 (da) Pallecontainer
EP3399976C0 (en) BENZOTHIAZOLE AMPHOPHILES
EP3473285A4 (en) Injector
DE112017000734A5 (de) Glycolsensor